ArticleFrontiers in oncology2026
Technetium-99m-marked sentinel lymph node biopsy for oral squamous cell carcinoma as a safe and effective procedure for patient and staff.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sentinel lymph node biopsy (SLNB) using [99mTc]Tc-albumin nanocolloid has emerged as a minimally invasive staging technique for selected patients with oral squamous cell carcinoma (OSCC). This study evaluates the feasibility of SLNB, the quality of patient selection, and radiation exposure during the procedure. Materials and methods: This retrospective single-center study included patients with oral squamous cell carcinoma clinically staged as cT1-cT2 cN0 who underwent SLNB using [99mTc]Tc-albumin nanocolloid. Sentinel lymph nodes were identified by preoperative imaging and intraoperative gamma probe detection. Histopathological findings guided further treatment. Radiation exposure to the surgeon was estimated using a point-source approximation. Clinical, pathological, and follow-up data were analyzed descriptively. Results: A total of 16 patients were included (11 males, 5 females; mean age 70.9 ± 11.1 years). Occult lymph node metastases were detected in 3 of 16 patients (18.8%), while tumor upstaging (pT>cT) occurred in 1 patient (6.3%). Sentinel lymph nodes were successfully identified in all patients. The mean administered technetium-99m activity was 100.9 ± 2.1 MBq, and surgery was performed after a mean interval of 26 h 03 min. The mean duration of surgery was 111.5 min. During surgery, the remaining radioactive activity averaged 5.1 MBq, and the surgeon's mean radiation exposure was 2.3 μSv. During follow-up, no regional nodal recurrences or delayed nodal failures were observed, and all patients were alive at the time of database lock. Conclusion: Sentinel lymph node biopsy may represent a feasible staging approach in carefully selected patients with early-stage oral squamous cell carcinoma and clinically negative lymph nodes (cN0). The procedure demonstrated a high identification rate, low estimated radiation exposure, and successful detection of occult nodal metastases. However, the limited sample size and follow-up duration warrant cautious interpretation of the oncologic outcomes, and further prospective studies are required before the role of SLNB relative to elective neck dissection can be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.